Search Results

You are looking at 221 - 230 of 452 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Scott M. Schuetze

. Adjuvant therapy of osteosarcoma—a phase II trial: Southwest Oncology Group study 9139 . Cancer 2004 ; 100 : 818 – 825 . 33. Voute PA Souhami RL Nooij M . A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial

Full access

Dawn J. Brooks

, 2015 . 2. Berry DA Cronin KA Plevritis SK Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators . Effect of screening and adjuvant therapy on mortality from breast cancer . N Engl J Med 2005 ; 353 : 1784 – 1792

Full access

Ashley E. Ross

. 10. Klein EA Yousefi K Haddad Z . A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy . Eur

Full access

John M. Skibber

-1064 . 36 Balani A Turoldo A Braini A . Local excision for rectal cancer . J Surg Oncol 2000 ; 74 : 158 - 162 . 37 Garcia-Aguilar J Mellgren A Sirivongs P Buie D . Local excision of rectal cancer without adjuvant therapy: a word of

Full access

Christine M. Coticchia, Jiang Yang, and Marsha A. Moses

Group experience . J Clin Oncol 1991 ; 9 : 1138 – 1150 . 6. Young RC Walton LA Ellenberg SS . Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials . N Engl J Med 1990 ; 322

Full access

Frank Qian Zhan, Vathani Sharon Packianathan, and Nathalie Charlotte Zeitouni

Oncol 2007 ; 25 : 1043 – 1047 . 71 Garneski KM Nghiem P . Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy . J Am Acad Dermatol 2007 ; 57 : 166 – 169 .

Full access

risks of postsurgical complications. 5 “How we thought about adjuvant therapy has changed,” said Dr. Gradishar. “Physicians used to look at the number of nodes as a determinant of whether a patient was a candidate for chemotherapy, as well as what kind

Full access

Matt Brow, J. Russell Hoverman, Debra Patt, Bill Herman, Diana Verrilli, Jody Garey, and Roy Beveridge

support (and your adopted pathway for any given instance) when it really matters—at the point of decision—can be expensive. Agreement on common definitions can also be difficult, even for elements as simple as what constitutes third-line or adjuvant

Full access

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem

hepatocellular carcinoma . Liver Transpl 2005 ; 11 : 1086 – 1092 . 14. Llovet JM Mas X Aponte JJ . Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation . Gut 2002 ; 50 : 123 – 128

Full access

Gayathri Nagaraj and Cynthia X. Ma

. Describe the ideal treatment with adjuvant chemotherapy for patients with estrogen receptor (ER)-positive HER2-negative lymph node-negative breast cancer. Case Report A 67-year-old otherwise healthy postmenopausal woman presented for adjuvant